2023 / 03

Next Paper
DOI: 10.47183/mes.2023.024

ORIGINAL RESEARCH

Polymorphism of interleukin control genes and risk of neoplasms in exposed individuals

Blinova EA1,2, Yanishevskaya MA1, Akleyev AV1,2
About authors

1 Ural Research Center for Radiation Medicine, Chelyabinsk, Russia

2 Chelyabinsk State University, Chelyabinsk, Russia

Correspondence should be addressed: Evgenia A. Blinova
Vorovskogo st., 68, bldg. A, Chelyabinsk, 454141, Russia; ur.mrcru@avonilb

About paper

Funding: the study received funding in the context of the Federal Target Program "Ensuring nuclear and radiation safety in 2016-2020 and up to 2030" (State Contract #11.313.21.2 of June 15, 2021).

Author contribution: EA Blinova — generalization of primary material, analysis and discussion of results, article text authoring; MA Yanishevskaya — statistical processing of primary data; AV Akleyev — study planning, article editing.

Compliance with the ethical standards: the study was approved by the Ethics Committee of the Urals Research Center for Radiation Medicine of the FMBA of Russia (Minutes #4 of June 8, 2023). All procedures on humans performed in the context of the study conform to the requirements of the 1964 Helsinki Declaration and its subsequent amendments or comparable ethical standards. Each participant of the study signed the voluntary informed consent form.

Received: 2023-06-09 Accepted: 2023-07-20 Published online: 2023-08-12
|
Table 1. Characteristics of participants of the study
Note: 1 — mean value ± standard deviation (min–max); 2 — mean value ± standard error (min–max)
Table 2. Occurrence of genotypes of the studied SNPs in exposed individuals with and without MN
Note: 1 — observed heterozygosity; 2 — expected heterozygosity; 3 — significance of deviation from the Hardy-Weinberg law (at p > 0.05); 4 — significance of the odds ratio indicator (OR).
Table 3. Indicators of systemic immunity in carriers of various genotypes of the studied SNPs, "Exposed without MN" group
Note: 1 — number in parentheses after name of the genotype is the number of its carriers among the participants; 2 — significance by Mann–Whitney U test; * — significance at p > 0.05, Mann–Whitney U test, IL content (pg/ml), between carriers of different genotypes.